That’s fair. I’m simply balancing the discussion on the timeline for approval if/when leronlimab is proven to treat TNBC. My thoughts are speculation just likes your thoughts and the thoughts of others are speculation. Like you said, a difference of 6-12 months for approval isn’t that big of a deal to a long term investor, but it is for patients. I’m interested to see how this plays out and if the FDA makes the right decision.